65岁及以上老年人COVID-19疫苗安全性监测
基于美国CMS覆盖30,712,101名老年人的数据,其中17,411,342名COVID-19疫苗接种者共接种34,639,937剂,采用每周序贯检验比较观察率与历史率。BNT162b2接种后肺栓塞、急性心肌梗死、弥散性血管内凝血、免疫性血小板减少症达统计信号阈值,进一步评估后仅肺栓塞仍达阈值。mRNA-1273和Ad26 COV2.S未发现统计信号。
要点
- BNT162b2接种后初步发现肺栓塞、急性心肌梗死、弥散性血管内凝血、免疫性血小板减少症4个结局达统计信号阈值。
- 进一步评估后仅肺栓塞仍达统计信号阈值,急性心肌梗死、弥散性血管内凝血、免疫性血小板减少症的RR不再达阈值。
- mRNA-1273和Ad26 COV2.S接种后未发现统计信号。
核心结论
- 该早期预警系统首次在老年人中识别出BNT162b2接种后肺栓塞、急性心肌梗死、弥散性血管内凝血和免疫性血小板减少症的时间关联。
- 早期预警系统不能证明疫苗导致这些结局,正在开展调整年龄和养老院居住等混杂因素的更稳健流行病学研究以进一步评估这些信号。
- FDA强烈认为COVID-19疫苗接种的潜在获益大于COVID-19感染的潜在风险。
研究设计与样本
- 使用美国医疗保险和医疗补助服务中心(CMS)数据,覆盖30,712,101名65岁及以上老年人。
- 数据时间为2020年12月11日至2022年1月15日,包含17,411,342名COVID-19疫苗接种者,共接种34,639,937剂。
- 评估COVID-19疫苗接种后14个结局,采用每周序贯检验,计算观察结局率与COVID-19疫苗接种前历史(或期望)率的率比(RR)。
主要发现
- BNT162b2接种后4个结局达到统计信号阈值:肺栓塞(RR=1.54)、急性心肌梗死(RR=1.42)、弥散性血管内凝血(RR=1.91)、免疫性血小板减少症(RR=1.44)。
- 进一步评估后,仅肺栓塞的RR仍达到统计信号阈值;急性心肌梗死、弥散性血管内凝血和免疫性血小板减少症的RR不再达到阈值。
- 接种mRNA-1273或Ad26 COV2.S疫苗后未识别出统计信号。
关键数值与推荐
- BNT162b2接种后肺栓塞RR=1.54。
- BNT162b2接种后急性心肌梗死RR=1.42。
- BNT162b2接种后弥散性血管内凝血RR=1.91。
- BNT162b2接种后免疫性血小板减少症RR=1.44。
- mRNA-1273和Ad26 COV2.S接种后未发现统计信号。
临床怎么用
- 该早期预警系统的发现可用于向政府机构、医疗保健提供者、利益相关方和公众提供疫苗安全信息并支持决策。
- 早期预警系统不能证明疫苗导致这些结局,需开展调整混杂因素(包括年龄和养老院居住)的更稳健流行病学研究进一步评估这些信号。
- FDA强烈认为COVID-19疫苗接种的潜在获益大于COVID-19感染的潜在风险。
局限性
- 早期预警系统不能证明疫苗导致这些结局。
- 需要开展调整混杂因素(包括年龄和养老院居住)的更稳健流行病学研究以进一步评估这些信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monitoring safety outcomes following COVID-19 vaccination is critical for understanding vaccine safety especially when used in key populations such as elderly persons age 65 years and older who can benefit greatly from vaccination. We present new findings from a nationally representative early warning system that may expand the safety knowledge base to further public trust and inform decision making on vaccine safety by government agencies, healthcare providers, interested stakeholders, and the public. METHODS: We evaluated 14 outcomes of interest following COVID-19 vaccination using the US Centers for Medicare & Medicaid Services (CMS) data covering 30,712,101 elderly persons. The CMS data from December 11, 2020 through Jan 15, 2022 included 17,411,342 COVID-19 vaccinees who received a total of 34,639,937 doses. We conducted weekly sequential testing and generated rate ratios (RR) of observed outcome rates compared to historical (or expected) rates prior to COVID-19 vaccination. FINDINGS: Four outcomes met the threshold for a statistical signal following BNT162b2 vaccination including pulmonary embolism (PE; RR = 1.54), acute myocardial infarction (AMI; RR = 1.42), disseminated intravascular coagulation (DIC; RR = 1.91), and immune thrombocytopenia (ITP; RR = 1.44). After further evaluation, only the RR for PE still met the statistical threshold for a signal; however, the RRs for AMI, DIC, and ITP no longer did. No statistical signals were identified following vaccination with either the mRNA-1273 or Ad26 COV2.S vaccines. INTERPRETATION: This early warning system is the first to identify temporal associations for PE, AMI, DIC, and ITP following BNT162b2 vaccination in the elderly. Because an early warning system does not prove that the vaccines cause these outcomes, more robust epidemiologic studies with adjustment for confounding, including age and nursing home residency, are underway to further evaluate these signals. FDA strongly believes the potential benefits of COVID-19 vaccination outweigh the potential risks of COVID-19 infection.
引用
- Wong HL, Tworkoski E, Ke Zhou C, et al. Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older. Vaccine. 2022. PMID: 36496287. doi:10.1016/j.vaccine.2022.11.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。